These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 26536031

  • 1. Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines.
    Galetti M, Petronini PG, Fumarola C, Cretella D, La Monica S, Bonelli M, Cavazzoni A, Saccani F, Caffarra C, Andreoli R, Mutti A, Tiseo M, Ardizzoni A, Alfieri RR.
    PLoS One; 2015; 10(11):e0141795. PubMed ID: 26536031
    [Abstract] [Full Text] [Related]

  • 2. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki T, Doi S, Yoshida H, Kohno S.
    Cancer Res; 2005 Feb 15; 65(4):1541-6. PubMed ID: 15735043
    [Abstract] [Full Text] [Related]

  • 3. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
    Nagashima S, Soda H, Oka M, Kitazaki T, Shiozawa K, Nakamura Y, Takemura M, Yabuuchi H, Fukuda M, Tsukamoto K, Kohno S.
    Cancer Chemother Pharmacol; 2006 Nov 15; 58(5):594-600. PubMed ID: 16520985
    [Abstract] [Full Text] [Related]

  • 4. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
    Pick A, Wiese M.
    ChemMedChem; 2012 Apr 15; 7(4):650-62. PubMed ID: 22354538
    [Abstract] [Full Text] [Related]

  • 5. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
    Lopez JP, Wang-Rodriguez J, Chang C, Chen JS, Pardo FS, Aguilera J, Ongkeko WM.
    Arch Otolaryngol Head Neck Surg; 2007 Oct 15; 133(10):1022-7. PubMed ID: 17938326
    [Abstract] [Full Text] [Related]

  • 6. Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells.
    Chen YJ, Huang WC, Wei YL, Hsu SC, Yuan P, Lin HY, Wistuba II, Lee JJ, Yen CJ, Su WC, Chang KY, Chang WC, Chou TC, Chou CK, Tsai CH, Hung MC.
    PLoS One; 2011 Oct 15; 6(6):e21428. PubMed ID: 21731744
    [Abstract] [Full Text] [Related]

  • 7. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW.
    Cancer Lett; 2009 Jun 28; 279(1):74-83. PubMed ID: 19232821
    [Abstract] [Full Text] [Related]

  • 8. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).
    Elkind NB, Szentpétery Z, Apáti A, Ozvegy-Laczka C, Várady G, Ujhelly O, Szabó K, Homolya L, Váradi A, Buday L, Kéri G, Német K, Sarkadi B.
    Cancer Res; 2005 Mar 01; 65(5):1770-7. PubMed ID: 15753373
    [Abstract] [Full Text] [Related]

  • 9. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.
    Li J, Cusatis G, Brahmer J, Sparreboom A, Robey RW, Bates SE, Hidalgo M, Baker SD.
    Cancer Biol Ther; 2007 Mar 01; 6(3):432-8. PubMed ID: 17312388
    [Abstract] [Full Text] [Related]

  • 10. The EGFR pathway regulates BCRP expression in NSCLC cells: role of erlotinib.
    Porcelli L, Giovannetti E, Assaraf YG, Jansen G, Scheffer GL, Kathman I, Azzariti A, Paradiso A, Peters GJ.
    Curr Drug Targets; 2014 Mar 01; 15(14):1322-30. PubMed ID: 25479544
    [Abstract] [Full Text] [Related]

  • 11. Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines.
    Bai XY, Zhang XC, Yang SQ, An SJ, Chen ZH, Su J, Xie Z, Gou LY, Wu YL.
    PLoS One; 2016 Mar 01; 11(3):e0149370. PubMed ID: 26943330
    [Abstract] [Full Text] [Related]

  • 12. Downregulated ABCG2 enhances sensitivity to topoisomerase I inhibitor in epidermal growth factor receptor tyrosine kinase inhibitor-resistant non-small cell lung cancer.
    Ohtsuka K, Ohnishi H, Morii T, Fujiwara M, Kishino T, Ogura W, Chiba M, Matsushima S, Goya T, Watanabe T.
    J Thorac Oncol; 2010 Nov 01; 5(11):1726-33. PubMed ID: 20975373
    [Abstract] [Full Text] [Related]

  • 13. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J, Zhang X, Wang F, Wang X, Yang K, Xu M, To KK, Li Q, Fu L.
    Oncotarget; 2015 Dec 29; 6(42):44643-59. PubMed ID: 26556876
    [Abstract] [Full Text] [Related]

  • 14. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Ashby CR, Fu LW, Ambudkar SV, Chen ZS.
    Cancer Res; 2007 Nov 15; 67(22):11012-20. PubMed ID: 18006847
    [Abstract] [Full Text] [Related]

  • 15. C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
    Bram EE, Ifergan I, Grimberg M, Lemke K, Skladanowski A, Assaraf YG.
    Biochem Pharmacol; 2007 Jun 30; 74(1):41-53. PubMed ID: 17481587
    [Abstract] [Full Text] [Related]

  • 16. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
    Sato H, Siddig S, Uzu M, Suzuki S, Nomura Y, Kashiba T, Gushimiyagi K, Sekine Y, Uehara T, Arano Y, Yamaura K, Ueno K.
    Eur J Pharmacol; 2015 Jan 05; 746():258-66. PubMed ID: 25455500
    [Abstract] [Full Text] [Related]

  • 17. Overcoming ABCG2-mediated drug resistance with imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors.
    Darby RA, Unsworth A, Knapp S, Kerr ID, Callaghan R.
    Cancer Chemother Pharmacol; 2015 Oct 05; 76(4):853-64. PubMed ID: 26351135
    [Abstract] [Full Text] [Related]

  • 18. BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib.
    Huang WC, Hsieh YL, Hung CM, Chien PH, Chien YF, Chen LC, Tu CY, Chen CH, Hsu SC, Lin YM, Chen YJ.
    PLoS One; 2013 Oct 05; 8(12):e83627. PubMed ID: 24391798
    [Abstract] [Full Text] [Related]

  • 19. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo.
    Leggas M, Panetta JC, Zhuang Y, Schuetz JD, Johnston B, Bai F, Sorrentino B, Zhou S, Houghton PJ, Stewart CF.
    Cancer Res; 2006 May 01; 66(9):4802-7. PubMed ID: 16651435
    [Abstract] [Full Text] [Related]

  • 20. Gefitinib enhances the antitumor activity of CPT-11 in vitro and in vivo by inhibiting ABCG2 but not ABCB1: a new clue to circumvent gastrointestinal toxicity risk.
    Inoue Y, Ikegami Y, Sano K, Suzuki T, Yoshida H, Nakamura Y, Nakagawa H, Ishikawa T.
    Chemotherapy; 2013 May 01; 59(4):260-72. PubMed ID: 24457609
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.